Navigation Links
Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 12, 2007 - Geron Corporation's (Nasdaq:GERN) telomerase inhibitor cancer drug, GRN163L, has demonstrated good pharmacokinetics and tolerability in its ongoing Phase I/II trial involving patients with chronic lymphocytic leukemia (CLL), according to data presented today by Alan Colowick, M.D., M.P.H., the company's president, oncology, at the Pan Pacific Lymphoma Conference in Maui, Hawaii.

Favorable Pharmacokinetics; Pharmacodynamics Consistent with Expectations

A pharmacokinetic analysis of three patients in the highest dose cohort (cohort 4, 160 mg/m2 IV/week) has shown transient peak plasma concentrations of GRN163L of approximately 10 ug/ml. This and other data indicate that the drug continues to exhibit favorable pharmacokinetic properties that are linear with respect to the doses tested so far.

Up to the current dose levels, no significant changes in telomerase activity or telomere length in the bulk circulating CLL cells of treated patients have been observed. These pharmacodynamic results are consistent with expectations because of the relatively short exposure of CLL cells in patients' blood to concentrations of drug capable of inhibiting telomerase.

Good Tolerability Profile

With dosing and accrual to cohort 4 continuing, patients treated at the current dose levels have tolerated the drug well, and the maximum tolerated dose has not yet been identified. Grade 1-2 partial thromboplastin time (aPTT) prolongation has been observed, and one patient each has experienced Grade 3 and Grade 4 thrombocytopenia.

Clinical Course

One patient in cohort 4 has completed two cycles of treatment, and stable disease has been observed. A second patient has had clinical findings consistent with tumor lysis syndrome, a transient metabolic abnormality resulting from the rapid destruction of malignant cells. This patient experienced a transie
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
2. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Telomerase Presentations at the AACR 2007 Annual Meeting
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
8. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
9. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
10. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
(Date:8/27/2015)... 2015 Major pharmaceutical and medical device companies and ... in Philadelphia on Oct. 20, discussing ... Hagy of HB Litigation Conferences has announced. ... at http://litigationconferences.com/?p=31886 The program is co-chaired ... Mahoney and Michelle Hart Yeary of Dechert LLP. ...
(Date:8/27/2015)... Aug. 27, 2015  Mytrus, a technology and services company revolutionizing ... electronic informed consent has received approval for use by ... It is the first time e-Consent technology will be ... . Mytrus was also the first ... clinical trial by the U.S. Food and Drug Administration ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... Services is pleased to announce the exciting addition of ... the new Manager of Minerals.  Dr. Al-Ammar brings with ... has over fourteen years of experience with ICP-MS and ... United States and Europe.  Additionally, Dr. Al-Ammar has seven ...
... 15, 2011 PPTA opposes New Jersey Assembly Bill 2003 ... 13 that imposes a new tax on therapies used to ... The Bleeding Disorders Treatment Fund by taxing the manufacturers of ... rebate. PPTA opposes any policy that would impose a tax ...
Cached Medicine Technology:Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing 2PPTA Opposes Tax on Blood Clotting Factor 2
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Summit , scheduled for October 27-29, 2015 in San Jose, CA. The ... will primarily focus on the void that exists where battery development and energy ...
(Date:8/27/2015)... Reading, PA (PRWEB) , ... August 27, 2015 , ... ... Therapy programs, Alvernia University now offers a third doctoral program at its main campus ... is a terminal degree program designed to prepare advanced practice nurses for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue ... of 2016. The new facility will be located at US Highway 19 North and Highlands ... on August 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
(Date:8/27/2015)... ... 27, 2015 , ... Z-Medica®, LLC, a leading developer and ... website http://www.Z-Medica.com , to further support the company’s corporate positioning. , The ... , “We launched a branded website last year to show our customers ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... river is in the news again, for all the wrong ... York state are warning boaters and others who use the ... million gallons of raw sewage that reached the river after ... health concern would be for anyone coming in contact with ...
... alarm for parents about a common myth: that children dont ... so-called brain attacks each year, and half of them end ... ,Strokes in children may occur even more ... sadly, strokes in children are sometimes not recognized and treated, ...
... a one-year-old child having his foot amputated has moved ... an explanation. ,In January, a fractured leg brought ... his limb was plastered below the waist. However, the skin ... necessitating its surgical separation on March 5. ,A ...
... boys affected by Duchenne muscular dystrophy. A new study has found ... their own for a longer period of time and reduce their ... in 3,500 boys. Symptoms start in early childhood and rapidly progress ... and 11. There is no cure for the disorder. ...
... Former US president Bill Clinton has once again lent a ... fallout between the Brazil government and drug giant Merck ... diffuse the situation. Clinching a deal with two Indian pharmaceutical ... the companies to provide second-line AVR drugs and a next ...
... prescribed a drug that reduces their estrogen levels. But ... is widespread concern about how the estrogen-reducing drugs - ... ,A study at Washington University School of Medicine in ... aromatase inhibitors, and researchers are calling for interested women ...
Cached Medicine News:Health News:Sewage Flows into Hudson River in a Torrent 2Health News:Sewage Flows into Hudson River in a Torrent 3Health News:Childhood Strokes Linked to Whiplash, Other Traumatic Injury 2Health News:Court Seeks Explanation from Hospital for Childs Amputation 2Health News:Daily Steroids Helpful for Boys Down With Muscular Dystrophy 2Health News:Clinton Foundation Eases Over-Pricing Of AIDS Drugs Once More 2Health News:Study to Investigate Gene's Effect on Bone Loss in Breast Cancer Patients 2
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: